Evaluate the Safety and Efficacy of Reslizumab for Patients With Eosinophilic Asthma
- Study Title
- Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Reslizumab (3.0 mg/kg) as Treatment for Patients (12 Through 75 Years of Age) With Eosinophilic Asthma
- Teva Identifier
- C38072/3085 | 2010-024540-15
- ClinicalTrials.gov Identifier
- NCT01290887
- Study Status
- Terminated
- Trial Condition(s)
- Eosinophilic Asthma
- Interventions
- Drug: Reslizumab
- Study Description
- Please refer to ClinicalTrials.gov for a description of the trial
Key Participation Requirements
- Gender
- Female, Male
- Age group
- Child, Adult, Older Adult
- Age Range
- 12 Years to 75 Years
- Trial Duration
- 06/01/2011 - 01/01/2015
- Phase
- Phase 3
